Theodorus Investment Funds

At Supernova Invest, we believe that top scientists and ambitious entrepreneurs can build a world where cutting-edge technologies shape the next generation of industry leaders. Our team provides unparalleled expertise and patient capital in the fields of healthcare, energy and environment, Industry 4.0, and digital technologies to support high-growth, deeptech start-ups and scale them globally. Leader and pioneer in DeepTech investment from inception to maturity. Supernova Invest’s founding team has more than 20 years of experience in deeptech venture capital. The company emerged in 2017 from the alliance between Amundi (Crédit Agricole Group) and the CEA, a key player in technological research. Supernova Invest is an independent management company, investing mainly across Europe. Investment decisions are made by the partners on the Investment Committee. With a total of about 100 investments and more than 70 portfolio companies, Supernova Invest benefits from a unique track record in deeptech, as reflected in its 30+ successful trade exits. The Supernova Invest team combines the best of technology and financing. What sets us apart is our ability to understand both the underlying technologies and the most complex deep tech business models. Our sectorsINDUSTRY 4.0 Engineering tools Production tools Embedded systems Logistics HEALTHCARE Medtech Biotech Diagnostics Discovery Tools DIGITAL TECHNOLOGIES Computing Semiconductors Cybersecurity Telecom ENERGY & ENVIRONMENT Cleantech Energy Transition Agritech Foodtech Our operating partners platform Supernova Invest collaborates with a selection of Operating Partners in order to industrialize our value-add support to our portfolio startups and facilitate the adoption of deeptech best practices. This program is an illustration of the Supernova Invest platform for Entrepreneurs, dedicated to the deeptech-specific challenges that they experience in scaling their startups. In the ever-growing landscape of deeptech funds, these operating partners incarnate our investor singularity as the pioneer and deep-tech leading VC firm. They were carefully selected, leveraging our unique understanding of deeptech-specific challenges and our join track record in getting deeptech startup to thrive. They embrace a one-of-kind, extensive scope of critical expertise to provide our entrepreneurs with the most elaborated deeptech support platform. The selection is the spearhead of a much wider network for fine-grained, custom-made support.

We are a European family office owned fund; we understand biosciences and medical technologies better than anyone else in the Private Equity and Venture Capital ecosystem. The capital of this fund has been generated by the family office's active bioscience investments across Europe, USA, and the APAC region since 1995. We understand the intricacies of commercializing bioscience discoveries. We also acknowledge that bioscience venture leadership requires deep courage - from founders and the investors that back them. What we look for We operate globally and only review investment opportunities submitted to us by our partner investment banks across the globe. If we believe in the transformative power of the discovery and the founder's ambition, this will suffice for us to determine the venture's potential. Our approach Upon receipt of a proposal from our investment bank partners, we will analyze the proposed deal, meet with the venture founders, and understand their vision. We will propose a deal size and structure. Execute a letter of intent and perform appropriate due diligence, negotiate, and execute a mutually acceptable binding contract. Release the required funding, close the transaction and work together to grow the business.

Wir sind der neue Frühphasen-Investor aus Mecklenburg-Vorpommern. Wir lieben Innovationen made by Founders in MV Und wir glauben an folgende Themen: Gesundheit & Pharma: Die globale Corona-Pandemie hat uns gezeigt, wie wertvoll Investitionen in unsere Gesundheit sind. Das haben wir verstanden. Bioökonomie & Agrarwirtschaft: Vor unserer Haustür wachsen viele natürliche Rohstoffe, die eine innovative und biobasierte Wirtschaft antreiben. Das gefällt uns. Nachhaltigkeit: Greentech ist der Schlüssel für eine saubere Zukunft. Das sehen wir auch und werden hier unseren Beitrag als Investor leisten. Unser Investmentfokus in a Nutshell Phase: Early-Stage Ticketgröße: EUR 100-300k Bereich: Agrar, Gesundheit, Pharma, Nachhaltigkeit, Digital Region: Mecklenburg-Vorpommern

We look for companies in Italy and selectively abroad. 5 KEY SECTORS Founded in 2016, today Indaco Venture Partners SGR is the largest independent Italian venture capital asset management company, with a strong specialization in companies that innovate in electronics, robotics and new materials, medtech, biotech – pharma and digital. EXPERIENCE The investment team managers have an extensive experience in venture investing in Italy and abroad and have executed a high number of successful exits, including IPOs and transactions with corporate partners.

Noetic invests globally to build emerging technologies in molecular therapeutics/biotech, digital health, medical devices, and wellness with a focus on mental health, pain, and other complications resulting from the central nervous system. About no•et•ic “From the Greek noēsis/ noētikos meaning inner wisdom, direct knowing, or subjective understanding” Noetic science refers to a multidisciplinary field that brings objective scientific tools and techniques together with subjective understanding to study the full range of human experience. Mission: Our mission is to nurture the scientific advancement of mental, emotional, and physiological health by investing in emerging therapies, modalities, and sciences that are committed to optimizing our human experience. Commitment: We are committed to developing sustainable therapies, products, and services that are innovative, safe, and accessible to create a better mental health landscape for current and future generations. Focus: CNS-targetted therapeutics and related sustainable solutions for mental health and physical well being.

First founded as a venture capital firm in 1999, IMM Investment has since become one of leading multi-asset alternative investment firms in Asia with $6.4 billion* of assets under management across three business segments (venture capital, growth equity and infrastructure) We continue to create significant value for our portfolio companies. Established in September 1999, IMM Investment Corp. is the leading alternative investment firm in Korea, focusing on Venture Capital, Mezzanine and Infrastructure. With longstanding trust of institutional investors, partners and investment professionals continue to create significant values for Portfolio companies, which consist of Information Technology, Healthcare/Biotech and Manufacturing. The Leading Investment Firm in Korea IMM Investment today is a leading firm in Korean alternative investment market. However, the position as a top player in the Korean capital market was not achieved in one day. IMM Investment has built up its track record with the strong management team based on partnership, working to increase the value of portfolio companies and distribute returns to LP investors. 1999~2006 _Growth Stage Korean VC industry emerged when ‘Special Law to Promote Venture Capital Companies' was enacted in 1997. IMM Investment was established in September 1999. In 2000, the company merged with GEO Investment and set foundation for future growth. In the initial years, IMM Investment focused on IT and Culture/Contents industry and Corporate Restructuring Company (CRC). Through outstanding performance from VC and CRC, IMM Investment built successful track records, and asset under management reached KRW 207bn by December 2006. 2007~2009 _Transition After enactment of the Financial Investment Services and Capital Markets Act (formerly indirect Investment Asset Management Business Act) in 2004, CRC was gradually replaced with PEF. In the end of 2006, IMM Investment spun-off Buyout business to IMM PE and, in 2008, spun-off Culture/Contents focus to Stonebridge Capital. During this time, some of the company’s successful investments include Celltrion(Biosimilar), Novelis Korea(Manufacturing, Flat-rolled aluminum products). 2010~Present _Emergence as a leading investment firm in Korea Based on the successful track record, IMM Investment raised several VC and PEF funds since 2010. Company currently manages total of 25 VC funds (AUM KRW 1,300bn) and 23 PEF (AUM KRW 6,400bn). In addition to VC, IMM Investment also made several investments in medium-to-large sized enterprises or infrastructures, notably Hanjin Newport, PSA Hyundai Pusan Newport Terminal, Hyundai LNG Shipping, and Incheon Total Energy Company. IMM Investment is currently actively pursuing both domestic and overseas investment opportunities.